A Prospective Trial of a Variable Compression System for Moderate to Severe Irritable Bowel Syndrome
PGP Health · NCT07540312
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–60 · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Not applicable
- Target enrollment
- 20
- US sites recruiting
- 3
- Study start
- May 21, 2025
- Record last updated
- April 29, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This prospective, interventional trial is intended to determine the safety and effectiveness of the Variable Compression System (VCS) device for Irritable Bowel Syndrome (IBS). This pilot study will enroll 20 subjects who will be required to wear the VCS device for a minimum of 6 hours a day and follow up at 21 days, 8 weeks, and 6 months post-device administration.
Being studied: Variable Compression System
Conditions: IBS (Irritable Bowel Syndrome)
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Written informed consent to participate in the trial as prescribed.
- Subjects with a weight of ≥50 kg and a body mass index between 18 and 40 kg/m2.
- Diagnosed with IBS(C)-constipation, IBS(D)-diarrhea, or IBS(M)-mixed patients' diagnosis according to Rome Criteria (moderate to severe).
Exclusion Criteria
- Allergy to the investigational device or any components or clinically significant allergies (excluding mild seasonal allergies), in the opinion of the investigator.
- Clinically relevant history of gastrointestinal, cardiovascular, musculoskeletal, endocrine, hematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic, immunologic, lipid metabolism disorders, or psychiatric disorders making implementation of the protocol or interpretation of the trial results difficult, or that would put the participant at risk by participating in the trial in the opinion of the Investigator.
- Hospital admission or major surgery within 30 days prior to screening.
- Pregnant, or positive urine pregnancy test.
- Participation in any other investigational drug trial within 30 days prior to screening.
- Participant with substance use disorder (SUD) and/or alcohol use disorder (AUD).
- Participant who has other conditions that may affect compliance in the opinion of the investigator, or who are unable to participate in the trial on his/her own.
- Participant with end stage organ disease.
Recruiting US locations
Central Florida Gastro Research
Kissimmee, FL 34741
Site contact: Muhammad Mohiuddin, MD
UChicago Medicine AdventHealth Medical Group Gastroenterology at Bolingbrook
Bolingbrook, IL 60440
Site contact: Hadi Saddiqui, DO, MPH
Delta Gastroenterology PC
Southhaven, MS 38671
Site contact: Ulric Duncan, MD
Study contacts (from the official record)
- Agim Beshiri, MD · +12623448468 · agim.beshiri@cmoproconsult.com